MorphoSys wins milestone as Novartis pushes into PhII/III; Astex shareholder tries to spur revolt against Otsuka buyout;

@FierceBiotech: ICYMI yesterday: What happens to the FDA in a government shutdown? Story | Follow @FierceBiotech

@JohnCFierce: Cancer immunotherapies turn a corner in race to megablockbuster market. Article | Follow @JohnCFierce

@EmilyMFierce: ICYMI yesterday: Government shutdown halts NIH research, CDC disease surveillance. Story from FierceBiotech Research | Follow @EmilyMFierce

@DamianFierce: Wall Street is less than thrilled with Stryker's $1.7B deal for MAKO, but CEO says just you wait. Story from FierceMedicalDevices | Follow @DamianFierce

> MorphoSys AG picked up a milestone today after its collaborator Novartis ($NVS) initiated a Phase II/III clinical trial in sporadic inclusion body myositis patients with the HuCAL-derived antibody bimagrumab (BYM338). Release

> Sarissa Capital says it's not happy with the terms of Otsuka's acquisition of Astex Pharmaceuticals ($ASTX). In an effort aimed at inspiring a stockholder revolt, Sarissa says it will not tender its shares, which represents about 5% of the biotech's equity. Release

> PDL BioPharma is providing $60 million in debt financing for Lensar. Release

Medical Device News

@FierceMedDev: ICYMI yesterday... Report: Blackstone, Bain, other equity firms bid for J&J's Ortho Clinical Diagnostics unit. Article | Follow @FierceMedDev

@MarkHFierce: Myriad's stock dived earlier this week over Dx reimbursement fears driven by what turned out to be a clerical error. Story from FierceDiagnostics | Follow @MarkHFierce

> Quest unloads colon cancer Dx business as revamp marches on. Report

> Given Imaging should climb onto the auction block, investor says. News

> Street sneers at Stryker's $1.7B Mako deal, but CEO stays upbeat. Story

> GE will test imaging agent on MS patients taking Biogen's Tysabri. More

Pharma News

@FiercePharma: MS cases grow by 10% in 5 yrs, with most in US, Europe. Drugs access a problem, esp in low-income countries. More | Follow @FiercePharma

@EricPFierce: The success of some drugs shortly after launch suggest stardom. Special report | Follow @EricPFierce

@CarlyHFierce: From today's edition of FierceBiomarkers: Molecular switch could control metastases, aid diagnosis in breast cancer. Article | Follow @CarlyHFierce

> PhRMA sues feds over new rule on orphan-drug discounts. Story

> Judge sweeps aside AstraZeneca shield against Nexium competitor. More

> Shire aims to win skeptical Europe over to ADHD drugs. Article

Biomarkers News

> Report: Biomarkers market to grow 18.5% by 2018. Story

> Medicare's rejection of Alzheimer's test leaves Lilly in the lurch. Article

> Quintiles looks to biomarkers to speed up cancer trials. Report

> Research finds possible biomarker for Parkinson's with mild cognitive impairment. News

Drug Delivery News

@MichaelGFierce: Vaginal polymer ring delivers long-term HIV-preventing drug. Item | Follow @MichaelGFierce

> Hypertension drug could help chemo infiltrate tumors. More

> John Theurer Cancer Center touts two oral lymphoma drug studies. Story

> Oral peptide delivery biz Enteris lands Nordic partnership. Report

> MIT nanoparticles help deliver vaccines to mucosal surfaces. More

> Medtronic lands U.S. approval of early-generation artificial pancreas. Article

Diagnostics News

> Singulex will jump into in vitro diagnostics backed by $55M in debt, equity. Item

> UCLA team develops superfast fluorescent camera with Dx benefit. Story

> MA company debuts Dx device that could dramatically speed up HIV, other tests. Report

> Chronix preclinical study boosts CLIA goal for cell-free DNA cancer test. More

> Myriad reimbursement scare sent stock on roller coaster ride. Article

> Roche, Pacific Biosciences forge clinical Dx deal. Story

And Finally… Investigators have been testing new designer brands of marijuana to determine what makes them so toxic to teens. Release

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.